| Name | Breast cancer (A:m6A) |
| Description | m6A levels are reduced in breast cancer samples due to a decrease in m6A methylases expression and an increase in demethylases expression; expression levels of METTL3, METTL14, WTAP and FTO were correlated with poor survival and cancer progression; m6A higher levels suppress cancer cell viability, inhibit MDA-MB-231 colony-formation abilities and cell migratory abilities.Expression levels of writers and readers differes according to the subtype of breast cancer ( luminal A/B vs. triple negative). |
| Related RNA reaction | A:m6A |
| Modified Transcript | None |
| Mapping Technology | None |
| Quantification techniques | m6A quantification, ELISA |
| Acronym | Full name | Enzyme Role | Organism | Comment |
|---|---|---|---|---|
| ALKBH5 | RNA demethylase ALKBH5 | None | Homo sapiens | |
| FTO | Alpha-ketoglutarate-dependent dioxygenase FTO | None | Homo sapiens | |
| METTL14 | N6-adenosine-methyltransferase non-catalytic subunit | None | Homo sapiens | |
| METTL3 | N6-adenosine-methyltransferase 70 kDa subunit | None | Homo sapiens | |
| WTAP | Pre-mRNA-splicing regulator WTAP | None | Homo sapiens |
| ID | Title | Authors | Journal | Details | ||
|---|---|---|---|---|---|---|
| 985 | Changes of N6-methyladenosine modulators promote breast cancer progression. | Lianpin Wu | BMC Cancer | [details] | 30953473 | 10.1186/s12885-019-5538-z |